A. Perez

Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.

J. Friedberg, S. Rosenberg, C. Klebanoff, 2016 .

287. Production of KTE-C19 (Anti-CD19 CAR T Cells) for ZUMA-1: A Phase 1/2 Multi-Center Study Evaluating Safety and Efficacy in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

J. Rossi, A. Bot, L. Navale, 2016 .

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

J. Friedberg, S. Rosenberg, C. Klebanoff, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

S. Rosenberg, M. Roberts, A. Mardiros, 2015 .